The initial success of Sildenafil undeniably revolutionized the drug landscape, but betting in companies strongly reliant on unbranded versions presents a uncertain picture. Despite early profits were impressive, the expiration of patents and the appearance of discounted alternatives have diminished market share. Consequently, a thorough evaluation